The remarkable successes achieved using combination therapy to treat systemic human immunodeficiency virus type 1 (HIV-1) infection suggest that combination microbicides, which include two or more active ingredients, may also provide a particularly effective means to prevent HIV-1 transmission. We have recently identified the compound PSMA, an alternating copolymer of polystyrene (PS) and maleic anhydride (MA), as a potential partner for our candidate microbicide polyethylene hexamethylene biguanide (PEHMB), a member of the polybiguanide family of compounds. In vitro studies of PSMA demonstrated that this compound is minimally cytotoxic and highly effective against both macrophage-and T celltropic strains of HIV-1. We hypothesize that the dissimilar mechanisms of action of PSMA and PEHMB may provide additive or synergistic activity against HIV-1. Experiments are now underway to identify optimal combinations of PSMA and PEHMB to be used in experiments to assess toxicity, anti-HIV-1 activity, and formulation strategies. These investigations will be used to confidently advance the preclinical development of PSMA and a combination microbicide containing both compounds toward human trials. [link 'here' using 'a href' to: <url>http://www.biomedcentral.com/content/pdf/1742-4690-2-S1-full.pdf</url>]</note> </supplement>
